Trial · NCT03057977
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) | Placebo | 21.00 | 95% Confidence Interval 19.13 to 22.96 | Patients with events/ 100 pt-yrs at risk | |
| Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) | 10 mg Empagliflozin | 15.77 | 95% Confidence Interval 14.19 to 17.44 | Patients with events/ 100 pt-yrs at risk | |
| Occurrence of Adjudicated Hospitalisation for Heart Failure (HHF) (First and Recurrent) | Placebo | 553 | HHF events | ||
| Occurrence of Adjudicated Hospitalisation for Heart Failure (HHF) (First and Recurrent) | 10 mg Empagliflozin | 388 | HHF events | ||
| eGFR (CKD-EPI) cr Slope of Change From Baseline | Placebo | -2.278 | Standard Error 0.229 | Milliliter/minute/1.73 meters squared | |
| eGFR (CKD-EPI) cr Slope of Change From Baseline | 10 mg Empagliflozin | -0.546 | Standard Error 0.227 | Milliliter/minute/1.73 meters squared | |
| Time to First Event in Composite Renal Endpoint: Chronic Dialysis, Renal Transplant or Sustained Reduction of eGFR(CKD-EPI)cr | Placebo | 3.07 | 95% Confidence Interval 2.33 to 3.91 | Patients with events/ 100 pt-yrs at risk | |
| Time to First Event in Composite Renal Endpoint: Chronic Dialysis, Renal Transplant or Sustained Reduction of eGFR(CKD-EPI)cr | 10 mg Empagliflozin | 1.56 | 95% Confidence Interval 1.06 to 2.17 | Patients with events/ 100 pt-yrs at risk | |
| Time to First Adjudicated Hospitalisation for Heart Failure (HHF) | Placebo | 15.55 | 95% Confidence Interval 13.94 to 17.24 | Patients with events/ 100 pt-yrs at risk | |
| Time to First Adjudicated Hospitalisation for Heart Failure (HHF) | 10 mg Empagliflozin | 10.75 | 95% Confidence Interval 9.45 to 12.13 | Patients with events/ 100 pt-yrs at risk | |
| Time to Adjudicated Cardiovascular (CV) Death | Placebo | 8.13 | 95% Confidence Interval 7.05 to 9.29 | Patients with events/ 100 pt-yrs at risk | |
| Time to Adjudicated Cardiovascular (CV) Death | 10 mg Empagliflozin | 7.55 | 95% Confidence Interval 6.51 to 8.67 | Patients with events/ 100 pt-yrs at risk | |
| Time to All-cause Mortality | Placebo | 10.71 | 95% Confidence Interval 9.46 to 12.04 | Patients with events/ 100 pt-yrs at risk | |
| Time to All-cause Mortality | 10 mg Empagliflozin | 10.06 | 95% Confidence Interval 8.85 to 11.34 | Patients with events/ 100 pt-yrs at risk | |
| Time to Onset of Diabetes Mellitus (DM) | Placebo | 10.62 | 95% Confidence Interval 8.42 to 13.07 | Patients with events/ 100 pt-yrs at risk | |
| Time to Onset of Diabetes Mellitus (DM) | 10 mg Empagliflozin | 9.31 | 95% Confidence Interval 7.27 to 11.60 | Patients with events/ 100 pt-yrs at risk | |
| Change From Baseline in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score at Week 52 | Placebo | -3.36 | Standard Error 0.69 | Score on a scale | |
| Change From Baseline in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score at Week 52 | 10 mg Empagliflozin | -1.30 | Standard Error 0.69 | Score on a scale | |
| Number of All-cause Hospitalizations (First and Recurrent) | Placebo | 1570 | Hospitalizations for any cause | ||
| Number of All-cause Hospitalizations (First and Recurrent) | 10 mg Empagliflozin | 1364 | Hospitalizations for any cause |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03057977/results